title: Experience with intraperitoneal alpha-2a interferon.
abstract: Eighteen patients affected with epithelial ovarian cancer have been treated by intraperitoneal alpha 2a-Interferon. The usual single dosage was 54 x 10(6) U at weekly intervals for four times (eight times in responders): 10 histologically confirmed complete remissions and 3 partial remissions have been obtained; the toxicity was represented by fever in the majority of the cases, by abdominal discomfort in some cases, and by a mild transitory neurological complication in 1 case. Seventeen of 18 patients were pretreated, and 11 of 18 had only cytologic and/or microscopic disease. alpha 2a-Interferon has proven to be very effective and moderately toxic in microscopic peritoneal disease of ovarian epithelial cancer previously treated with extensive surgery and intravenous cytotoxic chemotherapy.
authors: Division of Medical Oncology, University Hospital, Padua, Italy.
authors: M O
authors: MO
authors: Nicoletto
authors: M V
authors: MV
authors: Fiorentino
authors: O
authors: O
authors: Vinante
authors: A
authors: A
authors: Prosperi
authors: F
authors: F
authors: Tredese
authors: S
authors: S
authors: Tumolo
authors: G P
authors: GP
authors: Cima
authors: S
authors: S
authors: Monfardini
mesh_terms: D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins